Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
D'Sa, Shirley
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia	Recruiting	2/3	148	Europe	Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib	University College, London, Janssen-Cilag Ltd.	Waldenstrom Macroglobulinemia	03/30	03/30
PembroWM, NCT03630042 / 2018-001767-23: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia	Completed	2	17	Europe	Pembrolizumab, Rituximab	University College, London, Merck Sharp & Dohme LLC	Waldenstrom Macroglobulinemia	09/21	02/24